Rationale, design and objectives of ARegPKD, a European ARPKD registry study

نویسندگان

  • Kathrin Ebner
  • Markus Feldkoetter
  • Gema Ariceta
  • Carsten Bergmann
  • Reinhard Buettner
  • Anke Doyon
  • Ali Duzova
  • Heike Goebel
  • Dieter Haffner
  • Barbara Hero
  • Bernd Hoppe
  • Thomas Illig
  • Augustina Jankauskiene
  • Norman Klopp
  • Jens König
  • Mieczyslaw Litwin
  • Djalila Mekahli
  • Bruno Ranchin
  • Anja Sander
  • Sara Testa
  • Lutz Thorsten Weber
  • Dorota Wicher
  • Ayse Yuzbasioglu
  • Klaus Zerres
  • Jörg Dötsch
  • Franz Schaefer
  • Max Christoph Liebau
چکیده

BACKGROUND Autosomal recessive polycystic kidney disease (ARPKD) is a rare but frequently severe disorder that is typically characterized by cystic kidneys and congenital hepatic fibrosis but displays pronounced phenotypic heterogeneity. ARPKD is among the most important causes for pediatric end stage renal disease and a leading reason for liver-, kidney- or combined liver kidney transplantation in childhood. The underlying pathophysiology, the mechanisms resulting in the observed clinical heterogeneity and the long-term clinical evolution of patients remain poorly understood. Current treatment approaches continue to be largely symptomatic and opinion-based even in most-advanced medical centers. While large clinical trials for the frequent and mostly adult onset autosomal dominant polycystic kidney diseases have recently been conducted, therapeutic initiatives for ARPKD are facing the challenge of small and clinically variable cohorts for which reliable end points are hard to establish. METHODS/DESIGN ARegPKD is an international, mostly European, observational study to deeply phenotype ARPKD patients in a pro- and retrospective fashion. This registry study is conducted with the support of the German Society for Pediatric Nephrology (GPN) and the European Study Consortium for Chronic Kidney Disorders Affecting Pediatric Patients (ESCAPE Network). ARegPKD clinically characterizes long-term ARPKD courses by a web-based approach that uses detailed basic data questionnaires in combination with yearly follow-up visits. Clinical data collection is accompanied by associated biobanking and reference histology, thus setting roots for future translational research. DISCUSSION The novel registry study ARegPKD aims to characterize miscellaneous subcohorts and to compare the applied treatment options in a large cohort of deeply characterized patients. ARegPKD will thus provide evidence base for clinical treatment decisions and contribute to the pathophysiological understanding of this severe inherited disorder.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease

Autosomal recessive polycystic kidney disease (ARPKD) is a rare monogenic disease with a severe phenotype often presenting prenatally or in early childhood. With its obligate renal and hepatic involvement, ARPKD is one of the most important indications for liver and/or kidney transplantation in childhood. Marked phenotypic variability is observed, the genetic basis of which is largely unknown. ...

متن کامل

Patient information and informed consent to the participation in the ARPKD registry study ARegPKD

Your doctor has made the diagnosis of “autosomal recessive polycystic kidney disease” (ARPKD) for your child and has asked you to participate in our ARPKD patient registry study. With this form, we want to give you an overview over the purpose of the registry, as well as potential benefits and risks of your participation. Please take some time to read the following information carefully and ple...

متن کامل

Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study.

BACKGROUND AND OBJECTIVES In contrast to the improvement in our understanding of the pathogenesis and presentation of autosomal recessive polycystic kidney disease (ARPKD), data regarding the issue of kidney and liver transplantation in patients with ARPKD remain particularly scarce. Here, we report the results and outcome of renal and/or liver transplantation in a series of patients with ARPKD...

متن کامل

EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.

The goal of adjuvant anti-cancer therapies is cure with limited or no side effects, in particular long-term side effects with negative impact on quality of life. In the palliative setting disease control, quality of life and overall survival are important end points. Partly due to improvements in treatment, the population of cancer survivors is large and growing. However, anti-cancer drug-relat...

متن کامل

Pulmonary Hypertension Registry: a 10-Year Experience

Background: Pulmonary Arterial Hypertension (PAH), a fatal orphan disease, is defined as increased mean Pulmonary Arterial Pressure (mPAP) above 25 mm/Hg, Pulmonary Capillary Wedge Pressure (PCWP) below 15 mm/Hg, and pulmonary vascular Resistance over 3 Wood Unit (WU). Although Pulmonary Hypertension (PH) is a relatively prevalent disease, the idiopathic form (iPAH) is a rare disease with a pre...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 16  شماره 

صفحات  -

تاریخ انتشار 2015